RA – Treatments Poster I: RA Treatments & Their Safety
Friday, November 6, 2020
9:00 AM – 11:00 AM ET
Poster session.
Presentations:
9:00 AM – 11:00 AM ET
A Phase 1, Randomized, Open-label, Parallel Group, Single-dose Study to Compare the Pharmacokinetics and Safety of the Auto-injector and Pre-filled Syringe of CT-P17, a Proposed, Higher Concentration Biosimilar (100 mg/mL) Adalimumab, in Healthy Subjects Daniel E. Furst, MD – UCLA
9:00 AM – 11:00 AM ET
Predictors of Durable Clinical Response to Tofacitinib 11 Mg Once Daily with or Without Methotrexate in Patients with Rheumatoid Arthritis: Post Hoc Analysis of Data from a Phase 3b/4 Methotrexate Withdrawal Study Kunihiro Yamaoka, MD, PhD – Kitasato University School of Medicine
9:00 AM – 11:00 AM ET
A Multicenter, Randomized, Placebo-controlled, Double-blind Phase 2 Study of SHR0302 versus Placebo in Chinese Subjects with Moderate to Severe Active Rheumatoid Arthritis (RA) Xiaofeng Zeng – Department of Rheumatology, Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID)
9:00 AM – 11:00 AM ET
Safety Profile of Baricitinib for the Treatment of Rheumatoid Arthritis up to 8.4 Years: An Updated Integrated Safety Analysis Kevin Winthrop, MD, MPH – Oregon Health & Science University
9:00 AM – 11:00 AM ET
Safety of Baricitinib in Patients with Rheumatoid Arthritis: Interim Report from All-Case Post‑Marketing Study in Clinical Use Tatsuya Atsumi, MD – Hokkaido University
9:00 AM – 11:00 AM ET
Pharmacokinetics and Safety of CT-P17, a Proposed High Concentration (100 mg/mL) Adalimumab Biosimilar, in Comparison with EU-Approved Adalimumab and US-Licensed Adalimumab; Results of a Phase 1, Randomized, Double-blind, Three-arm, Single-dose Study in Healthy Subjects KyungSang Yu, MD – Seoul National University College of Medicine and Hospital
9:00 AM – 11:00 AM ET
Methotrexate Therapy Is Not Associated with an Increased Risk of Liver Fibrosis Assessed by the Fibrosis-4 Index Jerome Avouac – Paris Descartes University
9:00 AM – 11:00 AM ET
Fifty-Two Week Outcomes of Biologic-Naïve RA Patients Treated with Subcutaneous Abatacept in Japanese Multicenter Investigational Study (ORIGAMI Study) Naoto Tamura, MD – Juntendo University School of Medicine
9:00 AM – 11:00 AM ET
Upadacitinib Monotherapy in Methotrexate-naïve Patients with Rheumatoid Arthritis: Results at 72 Weeks Ronald F Van Vollenhoven, MD, PhD – Amsterdam UMC
9:00 AM – 11:00 AM ET
WITHDRAWN
9:00 AM – 11:00 AM ET
Efficacy and Safety of Filgotinib for Patients with Rheumatoid Arthritis with Inadequate Response to Methotrexate: 52-Week Results Bernard Combe, MD, PhD – CHU Montpellier Montpellier University
9:00 AM – 11:00 AM ET
Upadacitinib as Monotherapy in Patients with Rheumatoid Arthritis and Prior Inadequate Response to Methotrexate: Results at 84 Weeks Josef S. Smolen, MD – Medical University of Vienna
9:00 AM – 11:00 AM ET
Long-term Safety and Efficacy of Sarilumab over 5 Years in Patients with Rheumatoid Arthritis Refractory to Tumor Necrosis Factor Inhibitors Roy Fleischmann, MD – Metroplex Clinical Research Center and University of Texas Southwestern Medical Center
9:00 AM – 11:00 AM ET
Efficacy and Safety of Upadacitinib in Patients from China, Brazil, and South Korea with Rheumatoid Arthritis Who Have Had Inadequate Response to Conventional Synthetic Disease-modifying Antirheumatic Drugs Xiaofeng Zeng – Department of Rheumatology, Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID)
9:00 AM – 11:00 AM ET
Long-Term Safety and Effectiveness of Upadacitinib or Adalimumab in Patients with Rheumatoid Arthritis: Results at 72 Weeks Roy Fleischmann, MD – Metroplex Clinical Research Center and University of Texas Southwestern Medical Center
9:00 AM – 11:00 AM ET
Sustainability of Response to Upadacitinib as Monotherapy or in Combination Among Patients with Rheumatoid Arthritis and Prior Inadequate Response to Conventional Synthetic DMARDs Arthur Kavanaugh, MD – UCSD
9:00 AM – 11:00 AM ET
Sustainability of Response Between Upadacitinib and Adalimumab Among Patients with Rheumatoid Arthritis and Prior Inadequate Response to Methotrexate Peter Nash, MBBS, FRACP – Griffith University
9:00 AM – 11:00 AM ET
Incidence and Risk of Venous Thromboembolic Events Among Patients with Rheumatoid Arthritis Enrolled in the Upadacitinib Clinical Trial Program Ernest Choy, MD, FRCP – Cardiff University School of Medicine
9:00 AM – 11:00 AM ET
A Subgroup Analysis of Low Disease Activity and Remission from Phase 3 Study of Filgotinib in Patients with Inadequate Response to Biologic DMARDs Jacques-Eric Gottenberg, MD, PhD – Hôpital de Hautepierre
9:00 AM – 11:00 AM ET
Efficacy and Safety of Filgotinib in Methotrexate-Naïve Patients with Rheumatoid Arthritis: 52-Week Results Rene Westhovens, MD, PhD – University Hospitals KU Leuven
9:00 AM – 11:00 AM ET
Clinical Outcomes of Earlier versus Delayed Treatment of Iraqi Patients with Rheumatoid Arthritis with Etanercept Nizar Ani, MD – Baghdad College of Medicine
9:00 AM – 11:00 AM ET
Is It Realistic to Stop Prednisone in Early Rheumatoid Arthritis? A Subanalysis from the BeSt and IMPROVED Studies Raquel Dos-Santos, MD – Clinical University Hospital in Santiago de Compostela, Spain
9:00 AM – 11:00 AM ET
Impact of Concomitant Glucocorticoids on the Clinical Efficacy and Safety of Upadacitinib in Patients with Rheumatoid Arthritis: An Ad Hoc Analysis of Data from Three Phase 3 Studies Bernard Combe, MD, PhD – CHU Montpellier Montpellier University
9:00 AM – 11:00 AM ET
Should We Use BioDMARDS in First Intention in Early Rheumatoid Arthritis? : Results at 5 Years from the ERA Louvain Brussels Cohort Patrick Durez, MD – UClouvain
9:00 AM – 11:00 AM ET
tsDMARD Therapy Is Associated with More Initial Therapy Prolongations Compared to bDMARDs Both in Bionaive and Bioexperienced Patients with Rheumatoid Arthritis Diederik De Cock, PhD – KU Leuven
9:00 AM – 11:00 AM ET
Safety of Low Dose Methotrexate (MTX) and Tuberculosis (TB) Carol Hitchon, MD – University of Manitoba
9:00 AM – 11:00 AM ET
Efficacy of Long-term Treatment with Baricitinib 2 Mg in Patients with Active Rheumatoid Arthritis Alvin F. Wells, MD, PhD – Aurora Rheumatology and Immunotherapy Center
9:00 AM – 11:00 AM ET
Prevalence and Probability Assessment of Adverse Drug Reactions in Rheumatoid Arthritis Patients Receiving Intravenous Originator Biologics in Saudi Arabia: A Longitudinal Five Years Follow-up Study Hawazin Alhazzani, PharmD – King Saud University
9:00 AM – 11:00 AM ET
Similar Efficacy of Sarilumab Monotherapy (MONARCH) vs Sarilumab and Methotrexate Combination Therapy (MOBILITY B) in Patients with Rheumatoid Arthritis Gerd R. Burmester, MD – Charité – University Medicine Berlin
9:00 AM – 11:00 AM ET
Real Life Severe Infections in Patients with Rheumatoid Arthritis on Treatment with Biological Therapy and JAK Inhibitors LUCIA VEGA-ALVAREZ, MD – BASURTO UNIVERSITY HOSPITAL
9:00 AM – 11:00 AM ET
Impact of Upadacitinib or Adalimumab as Initial Therapy on the Achievement of 48-Week Treatment Goals in Patients with Rheumatoid Arthritis and Inadequate Response to Methotrexate: Post Hoc Analysis of a Phase 3 Study Eduardo Mysler, MD – 20171988064
9:00 AM – 11:00 AM ET
Integrated Safety of Filgotinib in Patients with Moderately or Severely Active Rheumatoid Arthritis Receiving Treatment for up to 5.5 Years Kevin Winthrop, MD, MPH – Oregon Health & Science University
9:00 AM – 11:00 AM ET
Effect of Dose Escalation of Subcutaneous Tocilizumab on Disease Activity in Patients with Rheumatoid Arthritis in a Randomized Controlled Trial Nora Singer, MD – The MetroHealth System
9:00 AM – 11:00 AM ET
Treatment Patterns of Biologic/Targeted Synthetic DMARDs for the Management of Rheumatoid Arthritis in Australia: An Analysis of the OPAL Dataset Helen Cooley, MD – Hobart specialist group
9:00 AM – 11:00 AM ET
Safety and Effectiveness of Tocilizumab in Patients with Renal Insufficiency in the Non-interventional Study ICHIBAN Christof Specker – Evangelisches Krankenhaus, Kliniken Essen-Mitte
9:00 AM – 11:00 AM ET
Abatacetp in Spanish Patients with Arthritis Rheumatoid and Interstitial Lung Disease. Multicenter Study of 263 Patients Carlos Fernández-Díaz, MD – HU Marqués de Valdecilla
9:00 AM – 11:00 AM ET
Characterization of Serious Infections with Upadacitinib in Patients with Rheumatoid Arthritis Kevin Winthrop, MD, MPH – Oregon Health & Science University
9:00 AM – 11:00 AM ET
Safety and Biological Activity of Rozibafusp Alfa in Subjects with Rheumatoid Arthritis: Final Results of a Phase 1b Randomized, Double-blind, Placebo-Controlled, Multiple Ascending Dose Study Stanley B. Cohen, MD – Metroplex Clinical Research Center
9:00 AM – 11:00 AM ET
Safety and Usability of Infliximab Administration by Auto-injector (AI) and Pre-filled Syringe (PFS) in Patients with Active Rheumatoid Arthritis (RA): Patient-reported Experience from a Multicenter, Randomized Controlled Pivotal Trial Rene Westhovens, MD, PhD – University Hospitals KU Leuven
9:00 AM – 11:00 AM ET
Safety Profile of Upadacitinib up to 3 Years of Exposure in Patients with Rheumatoid Arthritis Stanley B. Cohen, MD – Metroplex Clinical Research Center
9:00 AM – 11:00 AM ET
Gestational Desire and Certolizumab Pegol in Patients with Chronic Inflammatory Rheumatic Disease. Preliminary Results of the GESTAMAD Cohort Laura Gonzalez Hombrado, MD – Hospital Universitario del Tajo
9:00 AM – 11:00 AM ET
Adjudicated MACE and VTE in the Filgotinib RA Program: Integrated Analysis from Phase 2 and 3 Clinical Trials Christina Charles-Schoeman, MD – UCLA Medical Center
9:00 AM – 11:00 AM ET
Long-term Safety and Efficacy of Sarilumab over 5 Years in Patients with Rheumatoid Arthritis with 1 or >1 Prior Tumor Necrosis Factor Inhibitor Failures Roy Fleischmann, MD – Metroplex Clinical Research Center and University of Texas Southwestern Medical Center
